Efficacy and Safety Study of a Steroid/Antibiotic Combination Eyedrop to Treat Non-Bacterial Blepharitis

NCT ID: NCT01408082

Last Updated: 2021-11-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

917 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-10-31

Study Completion Date

2013-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the clinical efficacy and safety of ISV-502 compared to AzaSite® alone, Dexamethasone alone, and vehicle in the treatment of subjects with Non-bacterial Blepharitis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Blepharitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

ISV-502

Group Type EXPERIMENTAL

ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined)

Intervention Type DRUG

Azithromycin and Dexamethasone twice daily for 2 weeks

AzaSite

Group Type ACTIVE_COMPARATOR

Azasite

Intervention Type DRUG

Azasite twice daily for 2 weeks

Dexamethasone

Group Type ACTIVE_COMPARATOR

Dexamethasone

Intervention Type DRUG

Dexamethasone twice daily for 2 weeks

Vehicle

Group Type PLACEBO_COMPARATOR

Vehicle

Intervention Type OTHER

Vehicle twice daily for 2 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined)

Azithromycin and Dexamethasone twice daily for 2 weeks

Intervention Type DRUG

Azasite

Azasite twice daily for 2 weeks

Intervention Type DRUG

Dexamethasone

Dexamethasone twice daily for 2 weeks

Intervention Type DRUG

Vehicle

Vehicle twice daily for 2 weeks

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

AzaSite Plus

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Are at least 18 years of age at Visit 1 (Day 1, Baseline) of either sex and any race.
* Signature of the subject or legally authorized representative on the Informed Consent Form.
* Are willing and able to follow all instructions and attend all study visits.
* Are willing to avoid disallowed medication for the duration of the study.
* If female is of childbearing potential, agree to and submit a urine sample for pregnancy testing. Post menopausal is defined as having no menses for at least 12 consecutive months.

Exclusion Criteria

* Have known sensitivity or poor tolerance to any component of the Investigational Drug.
* Have an acute ocular infection (bacterial, viral or fungal) or active ocular inflammation other than Blepharitis in the study eye.
* Have used topical corticosteroid medications or topical ophthalmic solutions that the investigator feels may interfere with the study parameters.
* Have used any non-diagnostic topical ophthalmic solutions in the study eye.
* Be currently pregnant, nursing, or planning a pregnancy; or be a woman that has a positive urine pregnancy test.
* Currently suffer from alcohol and/or drug abuse.
* Have prior (within 30 days of beginning dosing) or anticipated concurrent use of an investigational drug or device.
* Have a condition or a situation which, in the Investigator's opinion, may put the subject at increased risk, confound study data, or interfere significantly with the subject's study participation.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sun Pharmaceutical Industries Limited

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Arizona Eye Center

Chandler, Arizona, United States

Site Status

Arizona Center for Clinical Trials LLC

Phoenix, Arizona, United States

Site Status

Cornea Consultants of Arizona

Phoenix, Arizona, United States

Site Status

Lugene Eye Institute

Glendale, California, United States

Site Status

United Medical Research Institute

Inglewood, California, United States

Site Status

Macy Eye Center

Los Angeles, California, United States

Site Status

North Valley Eye Medical Group, Inc.

Mission Hills, California, United States

Site Status

Eye Research Foundation

Newport Beach, California, United States

Site Status

North Bay Associates, Inc.

Petaluma, California, United States

Site Status

Martel Eye Medical Group

Rancho Cordova, California, United States

Site Status

Shasta Eye Medical Group, Inc.

Redding, California, United States

Site Status

San Diego Eye and Laser Center

San Diego, California, United States

Site Status

West Coast Eye Care Associates

San Diego, California, United States

Site Status

Florida Eye Microsurgicial Institute, Inc.

Boynton Beach, Florida, United States

Site Status

ZASA Clinical Research, LLC

Boynton Beach, Florida, United States

Site Status

Magruder Eye Institute

Orlando, Florida, United States

Site Status

Vision Eye Care Center

Palm Springs, Florida, United States

Site Status

International Research Center

Tampa, Florida, United States

Site Status

Richard Eiferman, MD

Louisville, Kentucky, United States

Site Status

Lakeview Optical

Gretna, Louisiana, United States

Site Status

Center for Sight, Inc.

Fall River, Massachusetts, United States

Site Status

Tauber Eye Center

Kansas City, Missouri, United States

Site Status

Ophthalmology Associates

St Louis, Missouri, United States

Site Status

Comprehensive Eye Care Ltd

Washington, Missouri, United States

Site Status

Abrams Eye Institute

Las Vegas, Nevada, United States

Site Status

Nevada Eye Care Professionals

Las Vegas, Nevada, United States

Site Status

Eye Care Associates of Nevada

Sparks, Nevada, United States

Site Status

David Ringel, OD PA

Sewell, New Jersey, United States

Site Status

Ophthalmic Consultants of Long Island

Lynbrook, New York, United States

Site Status

Ophthalmic Consultants of Long Island

Rockville Centre, New York, United States

Site Status

Ophthalmic Consultants of Long Island

Valley Stream, New York, United States

Site Status

South Shore Eye Care

Wantagh, New York, United States

Site Status

Charlotte Eye Ear Nose & Throat Associates, P.A.

Charlotte, North Carolina, United States

Site Status

Mundorf Eye Center

Charlotte, North Carolina, United States

Site Status

James Branch, MD

Winston-Salem, North Carolina, United States

Site Status

Eye Care Associates of Greater Cincinnati, Inc.

Cincinnati, Ohio, United States

Site Status

Eye Care Associates of Greater Cincinnati, Inc.

Fairfield, Ohio, United States

Site Status

Eye Care Associates of Greater Cincinnati, Inc.

Madeira, Ohio, United States

Site Status

Roseburg Research Associates, LLC

Roseburg, Oregon, United States

Site Status

Philadelphia Eye Associates

Philadelphia, Pennsylvania, United States

Site Status

Research Across America @ Wyomissing Optometric Center Inc

Wyomissing, Pennsylvania, United States

Site Status

Total Eye Care, PA

Memphis, Tennessee, United States

Site Status

David Shulman, MD

San Antonio, Texas, United States

Site Status

Sun Research Institute

San Antonio, Texas, United States

Site Status

Daynes Eye and Lasik

Salt Lake City, Utah, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Hosseini K, Bourque LB, Hays RD. Development and evaluation of a measure of patient-reported symptoms of Blepharitis. Health Qual Life Outcomes. 2018 Jan 11;16(1):11. doi: 10.1186/s12955-018-0839-5.

Reference Type DERIVED
PMID: 29325546 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

C-10-502-004

Identifier Type: -

Identifier Source: org_study_id